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TAVI pseudoaneurysm formation (PAF) is a frequent minor vascular
complication. The aim of the study was to compare the incidence of
post-TAVI PAF between the CoreValve (CV) using the St.Jude 18-F-
sheath, the Edwards Sapien XT valve (ESV-XT) using the 16-20 F
Esheath and the Edwards Sapien 3 (EDV-3) with the 14-16 f sheath.
METHODS Between April 2010 and October 2013, 574 pts (age 81.6 
0.41years) with high surgical risk (Euroscore 18.5 0.86%) underwent
successfully TAVI in local anesthesia using either the CV
(23,26,29,31mm), the ESVXT (23, 26, 29mm) or the ESV3 (23, 26,
29mm). Closure of the access site was performed in all pts by using the
ProStar XL 10 suture device. All TAVI pts (361 CV, 106 ESV-XT and 107
ESV-3) were examined serially the ﬁrst 5 days (day 1-3 and 5 post-
TAVI) after the procedure by ultrasound (US) for clinically silent
vascular complications. In case of PAF, ultrasound-guided manual
compression was done followed by compression bandage for another
24 h.
RESULTS In 34 pts (5.9%) we observed major vascular complication
after TAVI (17 [4.7 %] after CV, 7 [6.6%] after ESV-XT and 10 [9.3%]
after ESV-3, p¼0.076). In 123 pts (21.4%) we observed post-TAVI PAF,
which occurred signiﬁcantly more frequently after implantation of the
ESV-XT and ESV-3 than after implantation of the CV. CV versus ESV-
XT versus ESV-3 (60/361 [16.6%] versus 32/106 [30.2%] versus 31/107
[28.9%], p1¼0.01, p2¼0.002 and p3¼0.001). However in total only 8/
123 (6.1 %) patients with PAFs had to be treated surgically, the others
were treated either by ultrasound guided manual compression or
conservatively if smaller than 1 cm.
CONCLUSIONS Clinically silent PAF detected by routine US is a
frequent post-TAVI minor vascular complication which is more likely
to occur after ESV-XT and ESV-3 using the Esheath than after CV.
Although US-guided compression is highly effective, further minia-
turisation of TAVI devices and modiﬁcation of the Esheath design
might help to eliminate post-TAVI PAF.
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BACKGROUND The signiﬁcance of aortic regurgitation (AR) pre-
transcatheter aortic valve implantation (TAVI) implantation is un-
known. The present study aimed to assess the clinical repercussion of
AR in patients undergoing TAVI.
METHODS Retrospective analysis of 150 patients (mean age 817
years old, 43% male), from a tertiary centre prospective registry of 185
consecutive TAVI procedures, between November 2008 and
November 2014. The indication for TAVI was, aortic stenosis in 145
pts, degenerated biologic prosthetic valve in 3 pts and homograft
dysfunction in 2 pts. AR was found in 122 (75%) pts and was moderate
to severe in 33 (22%). We evaluated the clinical differences ate the
presentation and at a median follow up of 22 IQ [2-38] months,
stratiﬁed by the presence of moderate to severe AR, using the
following tests: Qui2, t-student and Mann- Withney.
RESULTS Patients with moderate to severe AR presented more
frequently with a NYHA functional class IV (21% vs 8.5%, p¼0.04) and
with a higher median NT-ProBNP (5190 IQ [1041-11457]pg/ml vs 1765
[795-3632] pg/ml, p¼0.02). During the follow up, they showed a greater
decrease of NT-proBNP (3295 IQ [1082-9621]pg/ml vs 1329 [267-2018]
pg/ml, p¼0.004) and a higher incidence of moderate to severe leak
(24% vs 8%, p ¼ 0.02). The incidence of leak in the overall population
was 65%, being moderate to severe in 16 pts (11%). In pts with leak, the
presence of pre-TAVI moderate to severe AR was associated with a
higher baseline NYHA functional class (p¼0.03) and with a more sig-
niﬁcant functional improvement (> 2 NYHA stages) during the follow
up (p¼0.04). The presence of AR was not associated with 30-day and 1-
year mortality. Seven pts with moderate to severe AR developed
moderate to severe leak. There was no differences between these pts
and the overall population, in what concerns to functional class, NT-
proBNP and cardiovascular events during the follow up.CONCLUSIONS Patients with moderate to severe aortic regurgitation
have a worse baseline clinical status and improve more signiﬁcantly
after transcatheter aortic valve implantation. The presence of AR was
associated with higher incidence of moderate to severe leak without
signiﬁcant clinical repercussion.
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BACKGROUND Transcatheter aortic valve implantation (TAVI) is the
treatment of choice for patients (pts) with severe symptomatic aortic
stenosis (AS) with high surgical risk. Many of these pts present with
chronic renal failure (CRF) or end-stage renal disease (ESRD). Chronic
and acute kidney injury might affect survival after TAVI though cur-
rent data is inconsistent. The aim of this study was to evaluate acute
kidney injury (AKI III) after TAVI under local anesthesia using either
the self-expandable 18-F-CoreValve prosthesis (MCV) or the 14-20F-
balloon expandable Edwards Sapien XT/3 prosthesis (ESV) in relation
to the pre-existent renal function and its association to clinical
outcome.
METHODS Between April 2010 and October 2014, 572 consecutive pts
(age 81.0  0.3years, 281 female) underwent successfully transfemoral
TAVI using either MCV or ESV in local anesthesia exclusively without
general anesthesia or deep sedation. Clinical events and acute kidney
injury (AKI) were evaluated according to the VARC-II criteria.
RESULTS Patients: 334 (58.4%) pts presented with NRF, 221 (38.6 %)
patients with CRF and 17 (2.97 %) pts with end-stage renal disease.
AKI III was 10.6 times higher in the CRF group than in the NRF
group: NRF vs CRF: 0.3% vs 3.2%, p> 0.01. 30-day clinical outcome:
30 day all-cause mortality differed signiﬁcantly between pts with
NRF and CRF and was highest in the ESRD group. NRF: 2.7%; CRF:
5.0%; ESRD: 23.5%). 30 day stroke rate was not signiﬁcantly
enhanced in pts with CRF or ESRD compared to pts with NRF. ( NRF
2.1 % ; CRF 2.3 % ; ESRD 0 %). Long-term clinical outcome: Longterm
mortality differed also signiﬁcantly beween the three groups: NRF
15.3 %; CRF 28.3 %; ESRD 58.8%). In contrast to 30 day-stroke rate,
long-term stroke was highest in the ESRD group. NRF 8.1 %; CRF 5.9
%; ESRD 17.6%. A multivariate analysis including atrial ﬁbrillation,
log Euroscore, age, sex, ejection fraction, type of valve (MCV or
ESV), AKN III and CRF, showed that only CRF represents an inde-
pendent predictor for 30 day mortality.
CONCLUSIONS Chronic and acute kidney injury is associated with
higher 30-day and longterm mortality, being highest in pts with ESRD.
TAVi should be indicated cautiously in patients with ESRD.
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BACKGROUND Due to a different design of the Cobalt chromium alloy
frame, the additional outerskirt to minimize paravalvular leakage and
the thinner struts of the stent frame, one might imagine that the
extent of platelet activation (PA) of the new Edwards Sapien 3 valve
(ESV3) might differ from the Edward Sapien XT valve (ESVXT).
Furthermore paravalvular leaks and hence residual aortic regurgita-
tion should be substantionally reduced The aim of our study was to
compare platelet aggregation (Agg) and platelet activation (PA)
observed with two different catheter valves, the ESV-XT and the
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platelet therapy (DAPT).
METHODS All Pts were loaded with 600 mg Clp and 500 mg ASA the
day before TAVI. Platelet aggregation (Agg) were evaluated in all pts
by the Multiplate system (Dynabyte, Munich, Germany) before (T0),
directly after intervention (T1) and on T2 (day1), on T3 (day2), and on
T4 (day3). PA was simultaneously assessed at the above time points by
measuring CD62 P expression by ﬂow cytometry.60 pts (age 82.50.8
years, 21 (35 % male) with severe aortic stenosis and high surgical risk
(log Euroscore 17.21.2 %) underwent successfully TAVI with the ESV-
XT and 114 pts (age 81.50.6 years years, log Euroscore 21.4 þ1.4 %, 43
(37.7% male) underwent TAVI with the ESV-3.
RESULTS Adenosindiphosphat (ADP)- , arachidonic acid (ASPI) – and
collagen (coll) induced platelet Agg was inhibited to the same extent
in both valve types directly after TAVI under dual antiplatelet therapy
[ESV-XT (T1) versus ESV-3 3 (T1) : AggADP, (AUC): 16 (11-24) versus 19
(13-30); p¼0.514; AggASPI (AUC): 13(5-19) versus 12 (6-17);
p¼0.436.Agg coll (AUC): 13(5-19) versus 12 (6-17); p¼0.436]. There was
no signiﬁcant difference in platelet drop between both valve types
between day 0 and day3. [ESV-XT (T0T3) versus ESV-3 (T0T3): 55.2 
4.2 versus 63.5 8.1; p¼0.364. ] However there was an enhanced
expression of CD62P directly after implantation in pts with ESV-XT
compared to pts with the ESV-3. [ESV-XT versus ESV-3 :median
(25th;75th percentile) mean immunoﬂuorescence : CD62P : 7.4 (6.8-
8.6) versus 6.6 (6-7.9), p¼0.014; ] CD 62 P expression was associated to
the grade of paravalvular aortic regurgitation (AR) after valve im-
plantation. TAVI patients with AR grade 1 exhibited a signiﬁcantly
higher CD62P expression than patients with AR grade 0 or Trace post
implantation [ CD62P expression in AR grade 1 versus CD62P expres-
sion in AR (grade 0 or Trace) : median (25th;75th percentile) mean
immunoﬂuorescence :7.9 (7.3-9.1) versus 7.1 (6.4 -8.0); p < 0.001) ]
CONCLUSIONS Although platelet inhibition was similar in both valve
types, platelet activation was signiﬁcantly enhanced in pts with the
ESV-XT compared to the ESV-3 valve and was associated to the
amount of residual AR which was signiﬁcantly reduced by ESV-3,
which may have implications for thromboischemic events following
TAVR procedure.
CATEGORIES STRUCTURAL: Valvular Disease: Aortic
KEYWORDS Paravalvular leak, Platelet function, TAVR
TCT-644
Comparison of the new balloon-expandable SAPIEN 3 versus the SAPIEN
XT. 30-day clinical outcome and echocardiographic data after transfemoral
aortic valve implantation
Suzanne Fateh-Moghadam,1 Sabrina Voesch,2 Tobias Geisler,3
Meinrad Gawaz,4 Wolfgang Bocksch5
1UC Tuebingen, Tuebingen, Germany; 2Eberhard-Karls University of
Tuebingen, tuebingen, BW; 3University Hospital Tübingen, Dept.
Cardiology, Tübingen, Germany; 4University Hospital Tübingen,
Department of Cardiology, Tübingen, BW; 5Eberhard-karls-Universität
Tübingen, Tubingen, Germany
BACKGROUND Post-TAVI paravalvular aortic regurgitation (PVL) is
still one of the most important limitation of ﬁrst generation trans-
catheter aortic valve prosthesis. The Edwards SAPIEN 3 (ESV-3)
transcatheter heart valve incorporates a paravalvular sealing system
with an active 3 dimensional coaxial positioning and should herewith
address the problem of PVL. The aim of this study was to compare 30-
day clinical outcome and especially the incidence and magnitude of
post-TAVI paravalvular aortic regurgitation (PVL) after CT-guided
implantation of the newer generation transfemoral 14/16F-ESV-3 to its
precursor model 16/20F-ESV-XT using the Heart Navigator algoritm
for all pts.
METHODS Between August 2012 and October 2014, 209 consecutive
with high surgical risk underwent successfully transfemoral TAVI in
local anesthesia using either the ESV-XT (23,26,29 mm) or the ESV-3
(23, 26,29mm). CT-imaging including the Heart Navigator algorithm
was used for prosthesis size selection and valve implantation plane
selection. Clinical events and post-TAVI PVL was evaluated after 30
days according to the VARC-II criteria.
RESULTS Patients: 102 pts (mean age 81.97  0.5 years) with severe
aortic stenosis (pmean 47.6 1.52mmHg, mean AVA 0.76  0.11 cm2)
and high surgical risk (mean log Euroscore-I 16.9  0.86%) underwent
successfully TAVI with the ESV-XT and 107 pts (mean age 81.4  0.
6years, mean log Euroscore-I 20.2  1.39 with the ESV-3 in local
anesthesia. Procedural outcome: Device success was 101/102 (99.2%)
in ESV-XT and 100% in ESV-3, respectively. Compared to TAVI withthe ESV-XT, the ESV-3 procedures had shorter mean ﬂuoroscopy time
(10.0  0.5 min in vs 11.8  0.5 min, p¼ 0003, and less contrast media
was needed (188.9  5.6 ml versus 170.4  4.7 ml, p¼0.04. The pro-
cedure time (skin-to-skin) was not signiﬁcantly different (108.3  4.6
min vs 101.3  3.6 min, p¼0.496). In-Lab strokes and death did not
occur in both groups. 30-day clinical outcome: 30 day all-cause mor-
tality was similar among both valves implanted. (ESV-XT vs ESV-3:
2.9% vs 1.9%; p¼0.494) as was major/minor stroke rate (ESV-XT vs
ESV-3: 3.9% vs 1.9%; p¼0.333) . There was no signiﬁcant difference
between the two valve types concerning major vascular complication.
(ESV-XT vs ESV-3: 6.9% vs 9.3%; p¼0.322) and in the rate of new
pacemaker implantation (ESV-XT vs ESV-3: 16.7% vs 12.1%,n.s. ). 30-
day echocardiographic data: The rate of No/Trace AR was signiﬁcantly
higher in the ESV-3 compared to the ESV-XT (ESV-3 vs ESV-XT: 89.7%
vs 37.3%; p< 0.001). Mild AR ist found in in 62.7% after ESV-XT and in
only 10.3% after ESV-3-implantation (p<0.001). There was no severe
AR in both groups, in the ESV-XT there were 2.9 % of patients with
moderate AR compared to 0 in ESV3.
CONCLUSIONS Clinical outcome for both valves is excellent. Mild AR
is signiﬁcantly more frequent after ESV-XT-implantation. The
persistence of the result over time needs to be determined in further
studies.
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BACKGROUND With the advent of transcatheter aortic valve
replacement (TAVR), surgically high-risk or inoperable patients can
now undergo invasive aortic valve treatment. However, predicting the
left ventricular (LV) functional recovery after TAVR is still
challenging.
METHODS We prospectively enrolled patients undergoing TAVR at
the Stanford Transcatheter Heart Valve Program who provided con-
sent for the study. We measured conventional echocardiographic
parameters and novel metrics of ventricular strain (LV global longi-
tudinal strain, LV-GLS), in which a more negative value represents
better LV function. Patients were divided into improvement and
deterioration groups according to change in LV ejection fraction (EF)
before and 1 month after TAVR.
RESULTS A total of 87 patients were included in this study. Overall,
mean age and mean STS-predicted 30 day mortality were 83.58.9
years and 8.374.4 %, respectively. Mean LVEF and AV gradient were
56.614.7 % and 51.415.1 mmHg, respectively. We identiﬁed 53 pa-
tients who showed improvement in LVEF (delta LVEF¼4.04.3 %)
and 34 patients who showed deterioration in LVEF (delta LVEF¼
-5.66.3 %). The two groups had no signiﬁcant difference in baseline
clinical characteristics, including LVEF (p¼0.43, Figure A) and mean
AV gradient (p¼0.54). However, the improvement group had lower
baseline LV-GLS (p¼0.02, Figure B) and less tricuspid regurgitation at
baseline (1.10.5 vs. 1.50.8 , p¼0.04).
